Can a patient undergoing radiation therapy safely receive the inactivated (injectable) influenza vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, patients undergoing radiation therapy can safely receive the inactivated (injectable) flu vaccine

Patients on radiation therapy should receive the inactivated influenza vaccine annually, as they are at increased risk for influenza complications and the vaccine is both safe and effective in this population.

Key Recommendations

Vaccine Type Selection

  • Use inactivated influenza vaccine (IIV) only - never the live attenuated nasal spray vaccine (LAIV) 1
  • LAIV is contraindicated in patients receiving immunosuppressive therapies, which includes radiation therapy 1
  • The inactivated vaccine contains no live virus and cannot cause infection 2

Safety Profile

The inactivated flu vaccine is safe for immunocompromised patients:

  • No serious adverse events have been reported in cancer patients receiving chemotherapy or radiation 3, 4
  • Side effects are mild and similar to healthy individuals: injection site soreness, low-grade fever, and malaise 3
  • No life-threatening or persistent adverse effects documented 3
  • The vaccine cannot cause influenza infection since it contains only inactivated virus 2

Efficacy Considerations

While radiation therapy may reduce immune response:

  • Most patients still mount protective antibody responses despite ongoing treatment 3, 4
  • Seroprotection rates remain adequate even during active therapy 4
  • The vaccine reduces influenza-related morbidity, mortality, and treatment interruptions 3, 4
  • Protection is particularly important given that cancer patients face higher risk of severe influenza complications 3, 5

Timing Recommendations

Optimal timing: Ideally vaccinate at least 2 weeks before starting radiation therapy 6

During active treatment: If not vaccinated beforehand, administer during radiation therapy rather than delaying 6, 4

  • The benefits of protection outweigh concerns about reduced immune response
  • Even suboptimal antibody responses provide meaningful clinical benefit 4

After treatment completion: Consider revaccination at least 3 months after therapy ends if vaccinated during treatment 6

Important Caveats

Household Contacts

  • All household members should receive annual flu vaccination 7, 8
  • Household contacts should receive inactivated vaccine preferentially (not LAIV) if the patient is severely immunosuppressed 1, 9
  • If household contacts receive LAIV, they should avoid contact with severely immunosuppressed patients for 7 days 9

Contraindications

The only true contraindications to inactivated flu vaccine are 10:

  • History of severe allergic reaction (anaphylaxis) to previous flu vaccine
  • History of Guillain-Barré syndrome within 6 weeks of prior flu vaccination

Egg allergy is not a contraindication - patients with egg allergy can safely receive any flu vaccine with appropriate precautions 10

Clinical Bottom Line

Annual influenza vaccination with inactivated vaccine is strongly recommended and safe for patients undergoing radiation therapy. The vaccine should be administered regardless of treatment timing, as the protection against potentially life-threatening influenza complications far outweighs any theoretical concerns about reduced efficacy during immunosuppression 11, 8, 6.

References

Research

Influenza vaccination in cancer patients undergoing systemic therapy.

Clinical Medicine Insights. Oncology, 2014

Research

Influenza vaccination in adult patients with solid tumours treated with chemotherapy.

European journal of cancer (Oxford, England : 1990), 2017

Research

Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020

Guideline

vaccination of adults with cancer: asco guideline.

Journal of Clinical Oncology, 2024

Related Questions

When should a patient on risankizumab (Skyrizi) receive the influenza vaccine?
For a healthy 55-year-old adult, should the influenza vaccine be the inactivated (killed) formulation rather than the live attenuated (nasal spray) vaccine?
Are there any reasons to avoid receiving the inactivated influenza vaccine one week before surgery?
Is it safe for a woman at one week gestation to receive Flucelvax (inactivated influenza vaccine)?
Can a patient undergoing active treatment for a neuroendocrine tumor receive an influenza vaccine, and what type and timing are recommended?
Which baseline and follow‑up laboratory tests should be ordered before initiating daptomycin and during therapy for a female patient of child‑bearing age, especially if she is on a statin or has potential muscle disease?
What is the appropriate management for a patient with an incomplete right bundle branch block and 1 mm ST‑segment elevation in leads V1 and V2?
How should silver sulfadiazine cream be applied for burns, including dosage, frequency, contraindications, and age restrictions?
How should acute hyponatremia presenting with seizures be treated?
In an elderly long‑term care patient with a known left bundle‑branch block who presents with new‑onset bilateral finger cyanosis but is otherwise stable, what is the appropriate initial management?
For a postmenopausal woman with recurrent uncomplicated urinary tract infections, is vaginal estrogen (estradiol) cream appropriate for prophylaxis, and what dosing schedule and contraindications should be considered?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.